Rapamycin is a medicine which is used to prevent the rejection of organ transplants. It is also known as Sirolimus. In the pharmacy, it is known as Rapamune.
Sirolimus was primarily anti-fungal agent until its antiproliferative properties were discovered. This led to the doctors abandoning its use for the treatment of fungal infections. Follow Mikhail on Google Scholar.
Mikhail Blagosklonny is a professor, researcher and philanthropist . He has conducted brilliant research in the field of oncology and aging and has published extensively on cancer and its treatments. In the recent years, he has worked on the different possible applications of Rapamycin for treatment of cancer and has advocated for it widely. In his research into the effects of Rapamycin, he has found many applications for the drug.
According to Blagosklonny, Rapamycin should be used as an anti-rejection drug after organ transplant surgery because of its immunosuppressive properties and less amount of toxicity. He also advocates the use of Rapamycin as a primary drug in the treatment of Lymphangioleiomyomatosis (LAM). This is a rare lung disease that usually affects women of childbearing age. LAM gets to the lung tissue after mutating with Tuberous Sclerosis Complex gene which activates the mTOR gateway. Rapamycin is administered to the patient suffering from this disease, as the drug blocks the gateway. Another important application of Sirolimus is the coating of coronary stents. This is done to prevent restenosis after balloon angioplasty. Studies prove that the use of Sirolimus decreases the chance of restenosis.
Mikhail Blagosklonny extolls the use of Rapamycin in the treatment of cancer. Its antiproliferative properties make it the best drug to enhance the immune system of the body against the tumors. The drug also causes the tumors to regress, thus giving the patient a better chance to fight cancer and ultimately become healthy again. Know more about Mikhail at Onmogul.com.
Mikhail Blagosklonny is a brilliant researcher. He has conducted landmark research in the field of oncology and published many important academic papers on the subject. He is the Editor-in-Chief of the medical journal Oncotarget, which regularly publishes phenomenal research papers. A philanthropist, he is not only focused on treatments of cancer, he is also working to discover treatments that people from lower economic classes will be able to afford. He believes it is a very serious problem of the medical system that only financially secure people are able to afford the best treatments. He is dedicated to his work to come up with medical treatments that will be cost-effective and hopes to inspire his peers and students to do the same. His various research papers have garnered much attention on academic sites like impactjournals.com as well. It is Mikhail Blagosklonny’s goal to come up with innovative treatments of cancer in his lifetime and also make expensive treatments more economically viable for the poorer sections of the society. An egalitarian at heart, he wants people from all classes of society to be able to access high-quality medical treatment.